Solifenacin
Urinary Bladder, Atony Of
Astellas Pharma IncSmall moleculePhase 4 / ApprovedDormant
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 43/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Urinary Bladder, Atony Of cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Oxybutynin Astellas Pharma Inc | Phase 4 | BB |
Estriol Texas Tech University Health Sciences Center | Phase 2/3 | B |
Uro Vaxom Buckinghamshire Healthcare NHS Trust | Phase 2 | B |
Rosemary University of Oran 1 | N/A | D |
LAVENDER OIL University of Oran 1 | N/A | D |
Same molecule, other indications
Solifenacin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →